Oncotarget

Vol 9, No 94

November 30, 2018

View Archive »

Order a Reprint

About The Cover

The cover for issue 94 of Oncotarget features Figure 6, "Progression free survival in LOH-high and LOH-low groups with operated patients censored at time of potentially curative surgery," by Smyth, et al.

Table of Contents

Editorial

PRMT5 inhibitors on the (myeloma) road

PRMT5 inhibitors on the (myeloma) road

https://doi.org/10.18632/oncotarget.26392

Annamaria Gulla, Teru Hideshima,  and Kenneth C. Anderson
36646-36647
PDF  |  Order a Reprint

The dual effect of pharmacological ascorbate on radiation: The best of both worlds

The dual effect of pharmacological ascorbate on radiation: The best of both worlds

https://doi.org/10.18632/oncotarget.26396

Joseph J. Cullen
36648-36649
PDF  |  Order a Reprint

Prostate cancer genomics and racial health disparity

Prostate cancer genomics and racial health disparity

https://doi.org/10.18632/oncotarget.26399

Vanessa M. Hayes, Weerachai Jaratlerdsiri,  and M.S. Riana Bornman
36650-36651
PDF  |  Order a Reprint

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management

https://doi.org/10.18632/oncotarget.26413

Salvatore Lopez, Burak Zeybek,  and Alessandro D. Santin
36652-36653
PDF  |  Order a Reprint

Research Papers

Genomic loss of heterozygosity and survival in the REAL3 trial

Genomic loss of heterozygosity and survival in the REAL3 trial

https://doi.org/10.18632/oncotarget.26336

Elizabeth C. Smyth, Catherine Cafferkey, Andrea Loehr, Tom Waddell, Ruwaida Begum, Clare Peckitt, Thomas C. Harding, Minh Nguyen, Alicia F. Okines, Mitch Raponi, Sheela Rao, David Watkins, Naureen Starling, Gary W. Middleton, Jonathan Wadsley, Wasat Mansoor, Tom Crosby, Andrew Wotherspoon, Ian Chau,  and David Cunningham
36654-36665
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Modulation of double-stranded RNA pattern recognition receptor signaling in ovarian cancer cells promotes inflammatory queues

Modulation of double-stranded RNA pattern recognition receptor signaling in ovarian cancer cells promotes inflammatory queues

https://doi.org/10.18632/oncotarget.26378

Maria Muccioli, Harika Nandigam, Tiffany Loftus, Manindra Singh, Amritha Venkatesh, Julia Wright, Michelle Pate, Kelly McCall,  and Fabian Benencia
36666-36683
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

SOX2 haploinsufficiency promotes impaired vision at advanced age

SOX2 haploinsufficiency promotes impaired vision at advanced age

https://doi.org/10.18632/oncotarget.26393

Leire Moreno-Cugnon, Ander Anasagasti, Maitane Ezquerra-Inchausti, Ander Izeta, Pedro de la Villa, Javier Ruiz-Ederra,  and Ander Matheu
36684-36692
Abstract  |  PDF  |  HTML  |  Order a Reprint

Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer

Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer

https://doi.org/10.18632/oncotarget.26401

Mariya Shapovalova, Julia Davydova, Christine Henzler, Mark Daniel, Scott M. Dehm, Christopher A. Warlick,  and Aaron M. LeBeau
36693-36704
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Reviews

Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer

Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer

https://doi.org/10.18632/oncotarget.26404

Harshita Shailesh, Zain Z. Zakaria, Robert Baiocchi,  and Saïd Sif
36705-36718
Abstract  |  PDF  |  HTML  |  Order a Reprint

Corrections

Correction: Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height

Correction: Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height

https://doi.org/10.18632/oncotarget.26429

Katrina Tatton-Brown, Sandra Hanks, Elise Ruark, Anna Zachariou, Silvana Del Vecchio Duarte, Emma Ramsay, Katie Snape, Anne Murray, Elizabeth R. Perdeaux, Sheila Seal, Chey Loveday, Siddharth Banka, Carol Clericuzio, Frances Flinter, Alex Magee, Vivienne McConnell, Michael Patton, Wolfgang Raith, Julia Rankin, Miranda Splitt, Volker Strenger, Clare Taylor, Patricia Wheeler, I. Karen Temple, Trevor Cole, Jenny Douglas,  and Nazneen Rahman
36719-36719
Correction  |  PDF

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

https://doi.org/10.18632/oncotarget.26431

Marina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, Alberto Fumagalli, Donata Sartori, Maria Rosaria Valerio, Mario Airoldi, Gabriella Moretti, Corrado Ficorella, Valentina Arcangeli, Lucrezia Diodati, Alberto Zambelli, Antonio Febbraro, Daniele Generali, Mirco Pistelli, Ornella Garrone, Antonino Musolino, Patrizia Vici, Michela Maur, Lucia Mentuccia, Nicla La Verde, Giulia Bianchi, Salvatore Artale, Livio Blasi, Michela Piezzo, Francesco Atzori, Anna Turletti, Chiara Benedetto, Maria Concetta Cursano, Alessandra Fabi, Vittorio Gebbia, Alessio Schirone, Raffaella Palumbo, Antonella Ferzi, Antonio Frassoldati, Claudio Scavelli, Luca Clivio,  and Valter Torri on behalf of The EVA Study Group
36720-36721
Correction  |  PDF


Copyright © 2018 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC